Evidence map›Paper›PMID 39404842›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Regulating the NMDA/NR2B signaling pathway mediates anticonvulsant, antineuroinflammation, and anti-oxidative stress effects of 1,3,benzothiazole derivative 1M in pentylenetetrazole-induced kindling in mice.

Neelum Gul Qazi, Ayesha Shafique Malik, Arooj Mohsin Alvi, Fawad Ali, Ismail Badshah, Humaira Nadeem, Sohaib Zafar Malik

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neelum Gul QaziDepartment of Pharmacy, Iqra University, Islamabad, 46000, Pakistan. dr.nenogull@gmail.com.
Ayesha Shafique MalikRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, 46000, Pakistan.
Arooj Mohsin AlviFaculty of Pharmacy, Ibadat International University, Islamabad, 46000, Pakistan.
Fawad AliDepartment of Pharmacy, Kohat University of Science and Technology, Kohat, 26000, Pakistan.
Ismail BadshahRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, 46000, Pakistan.
Humaira NadeemRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, 46000, Pakistan.
Sohaib Zafar MalikRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, 46000, Pakistan. sohaib.zafar@riphah.edu.pk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Periodic epileptic episodes are the hallmark of epilepsy, a prevalent neurological disorder. Research suggests a significant correlation between neuroinflammation and oxidative stress in a variety of neurological diseases, such as epilepsy. A substantial amount of evidence supports the role of N-methyl-D-aspartate receptors (NMDARs) in the progression of epilepsy. Although several lines of research have disclosed numerous biochemical effects of early seizures, its connection with disturbed NMDAR/NR2B subunit expression remains unclear. 2-Mercaptobenzothiazole (MBT) is a vital scaffold with several biological activities, and its various substitutes show promising anti-inflammatory potential. The current study aimed to investigate the newly synthesized 1,3-(benzothiazole-2-sulfanyl)-1-(morpholine-4-yl)ethan-1-one (1 M), a substituted MBT, for its neuroprotective potential in a mice model of pentylenetetrazole-induced epilepsy (PTZ), by modulating NMDA/NR2B pathway. The compound was tested for docking and simulation analysis, demonstrating a solid and stable bond with the NR2B subunit of NMDA. To ascertain the effects of 1 M, as well as to further illustrate its mechanism of neuroprotection via NMDA/NR2B in PTZ-induced kindling model, mice of either sex were given two doses of test compound, 1 M (10 mg/kg and 20 mg/kg). The behavioral assessments were evaluated using open-field, Y-maze, and elevated-plus maze tests, which indicated improved behavioral alterations caused by PTZ after 1 M treatment. The antioxidant profiling was done by estimating glutathione-S-transferase (GST), catalase (CAT), reduced glutathione (GSH), and LPO (lipid peroxidation) in hippocampal tissues, where the test compound 1 M significantly restored the depleted antioxidants, showcasing its antioxidant potential. Moreover, the cellular morphological damages induced by PTZ were detected by H&E staining, which was rescued after 1 M administration. Furthermore, the activation of the inflammatory pathway was confirmed by quantitative analysis of inflammatory mediators tumor necrotic factor (TNF-α), nuclear factor kappa B (NF-κB), and cylooxegenase2 (COX-2) by enzyme-linked immunosorbent assay (ELISA), where 1 M administration significantly ameliorated their expression. Furthermore, to demonstrate the involvement of the NR2B pathway, NR2B-antagonist ifenprodil was employed, and results were further confirmed through RT-PCR analysis. Our results, when considered collectively, indicate that 1 M may act by inhibiting the NR2B subunit of the NMDA receptor, subsequently mitigating downstream oxidative stress and inflammatory mediators through various pathways.

Indexed as

AnticonvulsantsAnti-Inflammatory AgentsAntioxidantsBenzothiazolesKindling, NeurologicNeuroprotective AgentsReceptors, N-Methyl-D-AspartateAnimalsDisease Models, AnimalEpilepsyMaleMiceOxidative StressPentylenetetrazoleSeizuresSignal TransductionAnticonvulsantsAnti-Inflammatory AgentsAntioxidantsBenzothiazolesNeuroprotective AgentsNR2B NMDA receptorPentylenetetrazoleReceptors, N-Methyl-D-AspartateAnti-inflammatoryAntioxidantEpilepsyIfenprodilNMDANR2B

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.